The Harm Record in the Paradigm Peptides Case: 54,000 Customers, 167 Victims
The Paradigm Peptides case is not just commercial fraud — it left real health harm behind.
The Department of Justice lists what customers reported: skin irritation and chronic acne, drops in natural testosterone that required replacement therapy, cardiac health issues, and stress, anxiety, and psychological problems up to suicidal ideation.
This article reviews that harm record, along with the full progression of one specific case.
1. Customer Reports Listed by the Department of Justice
The Department of Justice listed customer reports in the case record, mainly in four categories:
First, skin problems. Skin irritation and chronic acne.
Second, endocrine problems. Drops in natural testosterone, with some customers requiring replacement therapy.
Third, cardiac problems. Cardiac health issues.
Fourth, psychological problems. Stress, anxiety, and psychological problems up to suicidal ideation.
These reports came from actual customers and form the harm record in the case.
2. Why the Case Has a Name: Daniel Murphy
The case has a name attached because of Daniel Murphy, a 32-year-old marketing consultant from Tennessee.
He began taking Paradigm's SARMs in January 2023, believing they were a tested dietary supplement (BBC, 2026).
3. The Daniel Murphy Timeline
Here is the full progression of Murphy's case:
January 2023: Began taking Paradigm's SARMs.
Over the following months: developed insomnia, severe cystic acne, grandiose thinking, and then paranoia. He came to believe his wife was plotting against his business and that his mother-in-law meant to kill him. He had no history of mental illness.
December 2024: Ran out of product and began to improve.
February 2025: A letter from the Department of Justice told him that Paradigm's SARMs contained testosterone. He had a leftover bottle tested by an independent lab, and it came back positive (CBS News, 2026).
A psychiatrist, Dr Erik Messamore, diagnosed steroid-induced psychosis and gave evidence in the proceedings.
Murphy is also suing Paradigm in a civil case, which Kawa is contesting. That suit has not been decided.
4. A Detail Worth Sitting With
By the BBC's account, the FDA had seized and tested Paradigm's SARMs by September 2023.
Murphy kept taking them for more than a year after that, and nobody told him.
This detail is worth sitting with: the regulator already knew the product was problematic, but the customer continued taking it for more than a year.
5. The Risks of SARMs Themselves
For context, the FDA warns that even genuine SARMs carry risks including heart attack, stroke, liver injury, and psychosis (FDA, 2023).
Murphy was exposed to a different drug entirely, at a dose nobody measured.
This means the risk he faced was not the risk of SARMs themselves, but of an unknown drug at an unknown dose.
6. What the Restitution Figure Tells Us
The court ordered the two defendants to pay $78,317.52 in restitution, jointly.
Against $5 million in proceeds, this figure tells its own story:
If something goes wrong with a gray-market product, the realistic compensation is close to nothing.
7. 167 Victims
According to the BBC, 167 victims came forward for restitution.
That number only reflects those who came forward. Given the scale of 54,000 customers, the actual number affected may be far higher.
8. Summary
The harm record in the Paradigm Peptides case can be summarized as follows:
First, the Department of Justice listed four categories of customer reports: skin, endocrine, cardiac, and psychological.
Second, the Daniel Murphy case: from insomnia to steroid-induced psychosis.
Third, a key detail: the FDA knew of problems by September 2023, but the customer continued taking the product for over a year.
Fourth, restitution of $78,317.52, against $5 million in proceeds.
Fifth, 167 victims came forward, but the actual number may be higher.
These records remind us that the risks of the gray market are not just financial — they include real health consequences.
Frequently Asked Questions
What health problems did Paradigm customers report?
The Department of Justice lists: skin irritation and chronic acne, drops in natural testosterone, cardiac health issues, and stress, anxiety, and psychological problems up to suicidal ideation.
What happened to Daniel Murphy?
After taking Paradigm's SARMs, he developed insomnia, severe cystic acne, grandiose thinking, and paranoia, and was diagnosed by a psychiatrist with steroid-induced psychosis.
Why didn't the FDA notify customers after learning of the problem?
According to the BBC, the FDA had seized and tested the products by September 2023, but Murphy continued taking them for more than a year afterward, and nobody told him. The specific reasons for this process are not explained in the public record.
How much was the restitution?
The court ordered the two defendants to pay $78,317.52 in restitution, jointly, against about $5 million in proceeds.